Literature DB >> 7647986

Blockade by ONO-NT-012, a unique prostanoid analogue, of prostaglandin E2-induced allodynia in conscious mice.

T Minami1, I Nishihara, K Sakamoto, S Ito, M Hyodo, O Hayaishi.   

Abstract

1. Intrathecal (i.t.) administration of prostaglandin E2 (PGE2) to conscious mice was reported to induce allodynia, a state of discomfort and pain evoked by innocuous tactile stimuli through prostaglandin E receptor subtype EP1 and hyperalgesia through prostaglandin E receptor subtypes EP2 and/or EP3. In the present study, we investigated the effects of an EP1 antagonist on these sensory disorders by use of ONO-NT-012 or AH6809. 2. ONO-NT-012 dose-dependently antagonized the PGE2-induced allodynia but had no effect on the PGE2-induced hyperalgesia by the hot plate test. On the other hand, AH6809 blocked the PGE2-induced hyperalgesia at the highest dose examined (50 micrograms kg-1) but had no effect on the PGE2-induced allodynia. The i.t. injection of AH6809 or ONO-NT-012 alone did not have any effect on the response to noxious or innocuous stimuli. 3. Increasing doses (5 pg kg(-1)-500 ng kg-1) of ONO-NT-012 produced parallel shifts to the right of the dose-response curves to PGE2. The Schild plot regression line was linear and the slope was close to unity. The pA2 value against PGE2 was calculated to be 9.96. 4. The present study demonstrates that i.t. administration of PGE2 exerts allodynia through EP1 in the mouse spinal cord and that ONO-NT-012 is a highly potent, simple competitive antagonist for the PGE2-induced allodynia.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7647986      PMCID: PMC1908758          DOI: 10.1111/j.1476-5381.1995.tb16321.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  9 in total

1.  AH6809, a prostaglandin DP-receptor blocking drug on human platelets.

Authors:  R J Keery; P Lumley
Journal:  Br J Pharmacol       Date:  1988-07       Impact factor: 8.739

2.  Pharmacology of the allodynia in rats evoked by high dose intrathecal morphine.

Authors:  T L Yaksh; G J Harty
Journal:  J Pharmacol Exp Ther       Date:  1988-02       Impact factor: 4.030

3.  Ethical guidelines for investigations of experimental pain in conscious animals.

Authors:  Manfred Zimmermann
Journal:  Pain       Date:  1983-06       Impact factor: 6.961

4.  Evaluation of ZK110841 and AH6809, an agonist and an antagonist of prostaglandin DP-receptors on human platelets, with a PGD2-responsive cell line from bovine embryonic trachea.

Authors:  S Ito; E Okuda; K Sugama; M Negishi; O Hayaishi
Journal:  Br J Pharmacol       Date:  1990-01       Impact factor: 8.739

5.  Characterization of EP-receptor subtypes involved in allodynia and hyperalgesia induced by intrathecal administration of prostaglandin E2 to mice.

Authors:  T Minami; I Nishihara; R Uda; S Ito; M Hyodo; O Hayaishi
Journal:  Br J Pharmacol       Date:  1994-07       Impact factor: 8.739

6.  Nociceptive effects induced by intrathecal administration of prostaglandin D2, E2, or F2 alpha to conscious mice.

Authors:  R Uda; S Horiguchi; S Ito; M Hyodo; O Hayaishi
Journal:  Brain Res       Date:  1990-02-26       Impact factor: 3.252

7.  Involvement of glutamate receptors in allodynia induced by prostaglandins E2 and F2 alpha injected into conscious mice.

Authors:  Toshiaki Minami; Isao Nishihara; Rumiko Uda; Seiji Ito; Masayoshi Hyodo; Osamu Hayaishi
Journal:  Pain       Date:  1994-05       Impact factor: 6.961

8.  Allodynia evoked by intrathecal administration of prostaglandin E2 to conscious mice.

Authors:  Toshiaki Minami; Rumiko Uda; Shigeko Horiguchi; Sciji Ito; Masayoshi Hyodo; Osamu Hayaishi
Journal:  Pain       Date:  1994-05       Impact factor: 6.961

9.  Intrathecal morphine in mice: a new technique.

Authors:  J L Hylden; G L Wilcox
Journal:  Eur J Pharmacol       Date:  1980-10-17       Impact factor: 4.432

  9 in total
  3 in total

1.  Lack of tactile pain (allodynia) in lipocalin-type prostaglandin D synthase-deficient mice.

Authors:  N Eguchi; T Minami; N Shirafuji; Y Kanaoka; T Tanaka; A Nagata; N Yoshida; Y Urade; S Ito; O Hayaishi
Journal:  Proc Natl Acad Sci U S A       Date:  1999-01-19       Impact factor: 11.205

2.  Characterization of EP receptor subtypes responsible for prostaglandin E2-induced pain responses by use of EP1 and EP3 receptor knockout mice.

Authors:  T Minami; H Nakano; T Kobayashi; Y Sugimoto; F Ushikubi; A Ichikawa; S Narumiya; S Ito
Journal:  Br J Pharmacol       Date:  2001-06       Impact factor: 8.739

Review 3.  Prostanoid receptor antagonists: development strategies and therapeutic applications.

Authors:  R L Jones; M A Giembycz; D F Woodward
Journal:  Br J Pharmacol       Date:  2009-07-15       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.